Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

NCT ID: NCT01739673

Last Updated: 2018-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to evaluate the efficacy of ultraviolet-A (UVA) and riboflavin application (also often referred to as corneal collagen crosslinking) as a method to enhance treatment of infectious keratitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infectious Keratitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ultraviolet-A and riboflavin

Group Type EXPERIMENTAL

Ultraviolet-A and riboflavin

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ultraviolet-A and riboflavin

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects must be 18 years of age or older.
2. Ability to provide written informed consent.
3. Likely to complete all study visits.
4. Subjects must have one eye that with a diagnosis of infectious keratitis.

Exclusion Criteria

1. A corneal perforation.
2. Descemetocele.
3. Pregnancy or breastfeeding.
4. Active Herpes corneal disease.
5. Patient is unwilling or unable to comply with a medication regimen and follow up appointments.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cxlusa

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William Trattler, MD

Role: STUDY_DIRECTOR

Center For Excellence In Eye Care

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Schwartz Laser Eye Center

Scottsdale, Arizona, United States

Site Status

Davidorf Eye Group

West Hills, California, United States

Site Status

Corneal Consultants of Colorado, PC

Littleton, Colorado, United States

Site Status

Center for Excellence in Eye Care

Miami, Florida, United States

Site Status

Minnesota Eye Consultants

Minneapolis, Minnesota, United States

Site Status

Ophthalmology Associates

St Louis, Missouri, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

iCXL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.